| 產(chǎn)品編號 | bs-10006R |
| 英文名稱 | Rabbit Anti-CTLA4 antibody |
| 中文名稱 | 細胞毒性T細胞抗原-4（CD152）抗體 |
| 別 名 | CD 152; CD152; CD152 antigen; Celiac disease 3; CELIAC3; CTLA 4; CTLA-4; Cytotoxic T cell associated 4; Cytotoxic T lymphocyte associated 4; Cytotoxic T lymphocyte associated antigen 4; Cytotoxic T lymphocyte associated protein 4; Cytotoxic T lymphocyte associated serine esterase 4; Cytotoxic T lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; Cytotoxic T-lymphocyte-associated protein 4; GSE; IDDM12; CD152 isoform; CTLA4_HUMAN; GRD4; ICOS; Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4. |
 |
Specific References (5) | bs-10006R has been referenced in 5 publications.
[IF=7.644] Schl??er et al. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. (2016) Oncoimmunolog. 5:e1100789 IF(IHC-P) ; Human.
[IF=5.955] Weiqi Meng. et al. ZhenQi FuZheng formula inhibits the growth of colorectal tumors by modulating intestinal microflora-mediated immune function. AGING-US. 2022 Jun 15; 14(11): 4769–4785 WB ; Mouse.
[IF=5.811] Li Lanzhou. et al. Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function. FRONT PHARMACOL. 2022 May;0:1645 WB ; Mouse.
[IF=4.188] Jiang Minxiao. et al. Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer. Front Mol Biosci. 2021 May;8:380 IHC ; Human.
[IF=4.12] Seike, Masahiro, et al. "Histamine suppresses regulatory T cells mediated by TGF‐β in murine chronic allergic contact dermatitis." Experimental Dermatology(2015). IHC-F ; Mouse.
|
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat (predicted: Rabbit,Sheep,Cow,Dog) |
| 產(chǎn)品應用 | WB=1:500-2000,Flow-Cyt=1μg/Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 21kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CTLA-4/CD152: 75-170/223 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. Function: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Subunit: Homodimer; disulfide-linked. Binds to CD80/B7-1 and CD86/B7.2. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Note=Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation. Tissue Specificity: Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. Post-translational modifications: N-glycosylation is important for dimerization. Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. DISEASE: Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Similarity: Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: P16410 Gene ID: 1493 Database links: Entrez Gene: 1493 Human Entrez Gene: 100505288 Mouse Entrez Gene: 12477 Mouse Omim: 123890 Human SwissProt: P16410 Human SwissProt: P09793 Mouse Unigene: 247824 Human Unigene: 390 Mouse Unigene: 10259 Rat |
| 產(chǎn)品圖片 |
Sample:
Liver(Rat) Cell Lysate at 30 ug
Primary: Anti-CTLA4 (bs-10006R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 21 kD
Observed band size: 35 kD
Sample:
Liver(Mouse) Cell Lysate at 30 ug
Primary: Anti-CTLA4 (bs-10006R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 21 kD
Observed band size: 35 kD
Sample:
A549(Human) Cell Lysate at 30 ug
Primary: Anti-CTLA4 (bs-10006R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 21 kD
Observed band size: 35 kD
Blank control(blue): Molt-4 Cells(fixed with 2% paraformaldehyde (10 min) ). Primary Antibody: Rabbit Anti-CTLA4/FITC Conjugated antibody (bs-10006R/FITC), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG/FITC orange) ,used under the same conditions.
Blank control(blue):Mouse Spleen Cells(fixed with 2% paraformaldehyde (10 min)). Primary Antibody: Rabbit Anti- Phospho-c-Fos (Thr325)/FITC Conjugated antibody (bs-10006R /FITC), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG/FITC(orange) ,used under the same conditions.
Blank control: Hela(blue), the cells were fixed with 2% paraformaldehyde (10 min)
Isotype Control Antibody: Rabbit IgG(orange) ;
Secondary Antibody: Goat anti-rabbit IgG-PE (white blue),
Dilution: 1:200 in 1 X PBS containing 0.5% BSA ;
Primary Antibody Dilution: 1μg in 100 μL1X PBS containing 0.5% BSA(green).
Blank control: Raji(blue). Primary Antibody: Rabbit Anti-CTLA4 antibody(bs-10006R), Dilution: 5μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG (orange) ,used under the same conditions. Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
